We transplanted kidneys from a1,3-galactosyltransferase knockout (GalT-KO) pigs into six baboons using two different immunosuppressive regimens, but most of the baboons died from severe acute humoral xenograft rejection. Circulating induced antibodies to non-Gal antigens were markedly elevated at rejection, which mediated strong complement-dependent cytotoxicity against GalT-KO porcine target cells. These data suggest that antibodies to non-Gal antigens will present an additional barrier to transplantation of organs from GalT-KO pigs to humans.
Preformed antibodies directed against a specific oligosaccharide (Gala1-3Galb1-4GlcNAc; Gal) on the vascular endothelium of porcine blood vessels [1] [2] [3] [4] have precluded successful pig-to-higher-order primate xenotransplantation. Extensive pig-to-nonhuman primate experiments have shown that Gal-specific antibodies not only cause hyperacute rejection (which occurs in a few hours), but also initiate acute humoral xenograft rejection (AHXR; which occurs in a few days to a few weeks) [5] [6] [7] [8] . The recent production of cloned pigs lacking the galactosyltransferase enzyme (GalT-KO) 9, 10 raised hope that the organs from these animals would not only be spared from hyperacute rejection, but also would not be subject to AHXR. Here, we report our initial results of testing GalT-KO porcine kidneys in a life-supporting transplant model in baboons. The baboon recipients were immunosuppressed with either a multiagent immunosuppressive protocol, previously used to test transgenic porcine organs that express human decay accelerating factor (hDAF) 11 , or alternatively with a simpler 'tolerance-friendly' (a protocol with minimal immunosuppression) treatment strategy of immunosuppression that has been used clinically 12 .
We performed six kidney transplants in baboons using GalT-KO pigs as donors. We treated three of the baboons with a multiagent regimen that included a short course of thymoglobulin (ATG) followed by daily doses of tacrolimus, mycophenolate mofetil and steroids. We induced immunosuppression in the other three with a single high dose of ATG followed by monotherapy with tacrolimus ('light therapy'; Table 1a and Supplementary Methods online).
Both endothelial cells and lymphocytes, isolated from the GalT-KO donor pigs, had undetectable Gal expression measured by FACS when compared with the negative controls ( Supplementary Fig. 1 online) , confirming that the GalT-KO donor pigs were truly Gal-negative.
All recipient baboons had low levels of preformed non-Gal-specific IgG and IgM (Table 1b) before transplantation. Furthermore, sera collected from the recipient baboons before transplantation showed similar levels of complement-dependent cytotoxicity (CDC) against GalT-KO porcine lymphocytes as controls (Fig. 1a) . None of the GalT-KO porcine grafts in this study developed hyperacute rejection. (Fig. 1b) , despite the fact that peripheral lymphocyte counts were well controlled at a level of less than 0.5 Â 10 9 cells/l ( Supplementary Fig. 2 online) . AHXR was coincident with acute thrombocytopenia and proteinuria followed by marked elevations in serum creatinine, reduction of urine output and increase of non-Gal-specific antibody ( Fig. 1c and Supplementary Fig. 2 online) . Terminal pathology analysis from these four animals showed classic features of severe AHXR, characterized by massive interstitial hemorrhage, infarction, necrosis, thrombosis and loss of tubules with polymorph infiltration and massive deposition of IgG, IgM, C3, C4d (despite complement depletion with cobra venom factor) and platelets ( Fig. 1d) . There was no notable change in the ELISAmeasured levels of either Gal-specific IgG or IgM in the sera of recipient baboons during the entire follow-up transplant period ( Supplementary Fig. 3 online) . The other two baboons (67-03 and 65-03) died from Gram-negative bacterial sepsis or gastrointestinal bleeding on postoperative day 10 and 9, respectively. The pathology of renal grafts in these two cases showed only mild rejection (Grade I AHXR and/or AHXR; Table 1b) .
Despite low levels of preformed antibodies to non-Gal antigens before transplantation, the porcine-specific antibodies were markedly induced after grafting. In three of the four baboons that developed severe AHXR, circulating non-Gal IgG antibodies against donor lymphocytes increased 7-26-fold from baseline to the time of rejection (Table 1b and Fig. 1c ). There was also a 1.5-2.5-fold increase of antinon-Gal IgM levels in these three animals (Table 1b and Fig. 1c ). The fourth baboon (66-03) had only a moderate increase in non-Galspecific IgG levels at the endpoint, but there was a threefold increase in non-Gal-specific IgM levels (Table 1b) . Finally, the sera collected at the time of AHXR in these four baboons showed strong CDC (57.5-66.8%) against lymphocytes from GalT-KO pigs (Fig. 1a) . Similar results also were obtained when vascular endothelial cells were targets (Fig. 1c) . The xenografts of baboons 67-03 and 65-03, which died from infection (65-03) or gastrointestinal bleeding (67-03) when AHXR or ACXR was only Grade I, had minimal elevations in nonGal-specific IgG antibody levels and no increase in non-Gal-specific IgM levels (Table 1b) . At the endpoint, the sera collected from these two baboons showed low titers of CDC (o30%) against GalT-KO porcine lymphocytes (Fig. 1a) . The magnitude of the response of induced antibodies to non-Gal antigens, including CDC to GalT-KO lymphocytes or endothelial cells, was well associated with severity of rejection, suggesting that induced antibodies against non-Gal epitopes were responsible for AHXR. To determine whether there were specific molecules that induced production of antibodies to non-Gal proteins during rejection, we performed western blotting using baboon sera against GalT-KO pig endothelial cells (Supplementary Methods online) . Incubation of baboon preoperative sera with the porcine endothelial cell lysate showed multiple bands (Fig. 1e) . When incubated with sera collected at the endpoint of rejection, one of these bands at molecular weight of 47 kDa was enhanced in all baboons except 66-03, in which the results were obscured by intravenous immunoglobulin the baboon received (Fig. 1e) . These results indicate that a protein of 47 kDa isolated from porcine endothelial cells may be a major protein antigen that induced non-Gal antibody production during rejection.
Our results were notably different from those reported by others 13,14 who transplanted kidneys and hearts from GalT-KO miniature pigs. In those studies, elevated levels of antibodies against non-Gal antigens were not reported. Different immunosuppressive protocols, thymic radiation, cotransplantation of donor thymus, two kinds of GalT-KO pigs or different sources of the baboons may have contributed to the difference in the outcome. The inclusion of a CD154-specific monoclonal antibody in the immunosuppressive protocol used in these studies might effectively inhibit elicited antibodies 13, 14 . The clinical use of this antibody, however, has been hampered by its thrombotic tendencies 15 . Furthermore, a high complication rate and mortality in their kidney transplant recipients were noted in their report 13 . We previously used the same multiagent immunosuppressive protocol used in this study combined with the neutralization of Gal-specific antibodies in an hDAF pig-to-baboon kidney transplant model 11 . A median 13-d survival (range, 7-75 d) was achieved in this study. These data suggest that, in the presence of an induced antibody response, genetic depletion of Gal antigens does not provide a major benefit in xenograft survival.
In conclusion, kidneys from GalT-KO pig donors are not hyperacutely rejected by baboons under different immunosuppressive regimens. The problem posed by AHXR, however, has eluded solution. In our studies, AHXR was caused by induced antibodies to non-Gal antigens, and it seems essential to prevent this. Results from current studies in nonhuman primates are not promising enough to justify clinical trials. The future of xenotransplantation should emphasize further modification of donors, such as the combination of hDAF, GalT-KO, deletion of non-Gal antigens and adding a gene to inhibit coagulation dysregulation, rather than using more potent immunosuppressive agents in recipients.
Note: Supplementary information is available on the Nature Medicine website. 
